Abstract. To date, lung cancer is one of the leading causes of cancer mortality with short overall survival despite adequate therapy. New immunotherapeutic strategies using peptides derived from tumor-associated antigens (TAAs) can induce a specific cytotoxic T cell (CTL) response leading to a targeted tumor cell death. In the present study, we addressed whether there are further significant immunogenic candidate targets that may induce strong immune reactions with a high frequency in lung cancer patients eligible for cellular immunotherapeutic approaches, such as in a polyvalent vaccination approach. In this study, we investigated specific CTL responses of 14 HLA-A * 0201-positive patients (of 33 screened patients) with non-small cell lung cancer (NSCLC; n=12) or small cell lung cancer (SCLC; n=2) against several known and novel TAA-derived peptides from lung cancer and/or other tumor entities, by measuring granzyme B (GrB) and/ or interferon γ (IFNγ) secretion using enzyme-linked immunospot (ELISpot) analysis. Specific T cell responses could be detected for hTERT (4/13), two MAGE-A3-derived peptides (4/13 and 3/13, respectively), RHAMM (4/14), PRAME (8/14), G250 (7/12), survivin (3/13), HER2 (5/10) and WT1 (2/14), but also novel epitopes derived from Aurora kinase A (4/13) and B (5/13). Additionally, simultaneous CTL responses against the different peptides were examined and specific T cell responses against at least one of these TAAs could be detected in 13/14 (93%) patients. It could be shown that all patients with immune reactions against RHAMM and hTERT showed also immune responses against PRAME. Furthermore, patients with CTL responses against the Aurora kinase A peptide (Aura A1) also demonstrated a response against the Aurora kinase B peptide (Aura B1). Taken together, we showed that these TAA-derived peptides induce frequent specific T cell responses in patients with metastatic lung cancer and are, therefore, novel candidates for targeted immunotherapies and polyvalent approaches.
Introduction
In recent years, targeted therapies in the treatment of lung cancer have been implemented. Aside from thyrosine kinase inhibitors targeting EGFR and EML4-ALK, such as gefitinib, erlotinib and crizotinib as well as monoclonal antibodies against VEGFR (bevacizumab), specific therapies using cellular immunity have also been established or are in clinical examination (1) (2) (3) . It is known that T cell mediated immune responses can play a crucial role in tumor defense; tumor cells can be efficiently killed by specific T cells of the immune system (4). T cell activating antibodies against CTLA-4 (ipilimumab) and against the inhibitory T cell receptor programmed death-1 (PD-1) showed promising results against lung cancer in clinical testing (5, 6) . Active immunotherapies induce a specific immune response by recognizing epitopes being expressed in the tumor cell surface. Due to their association with tumor cells, these epitopes are called tumor-associated antigens (TAAs). TAAs are exclusively expressed and/or overexpressed in tumor cells, and are therefore useful to induce a tumor-specific immune response without harming healthy organs lacking TAA-expression (7) (8) (9) . In the past years, several TAAs in hematological and oncological neoplasms have been identified. These TAAs are proteins or receptors playing an important role in cell cycle, proliferation and differentiation (10, 11) .
The primary objective of active cancer immunotherapy is the induction of targeted cell death by activated specific CD8 + cytotoxic T cells (CTLs) (12, 13) . These activated CTLs recognize tumor cells that display the corresponding peptide derived from TAAs by MHC class I molecule on their surface which leads to a differentiation and expansion of CTLs and finally results in induction of lyses of the peptide presenting cells by the release of cytotoxins including perforin, granzymes and granulysin (14) (15) (16) patients and phase III trials are ongoing (17) (18) (19) . Tumor vaccination seems to be a promising strategy especially in situations of reduced lung tumor load, i.e. in maintenance therapy after induction chemotherapy or for patients with a low tumor load in further treatment lines (2, 20) . Aside from single peptide vaccination, peptide mixtures may be a potent strategy inducing cancer-defending immunity. It was demonstrated that immune responses to multipeptide vaccine IMA901 were associated with prolonged overall survival in patients with advanced renal cell cancer (21) . Therefore, it is important to identify TAA-derived peptides inducing CTL response in lung cancer that are potential candidates for developing potent single or polyvalent vaccines.
Materials and methods
Blood samples and preparation. A total of 33 patients were screened for HLA-A * 0201 expression (see below) and subsequently analyses were performed in 14 HLA-A * 0201-positive patients with diagnosed lung cancer, either non-small cell lung cancer (NSCLC; n=12; 8 adenocarcinoma and 3 squamous cell carcinoma, 1 sarcomatoid carcinoma) or small cell lung cancer (SCLC, n=2). Clinical characteristics of analyzed patients including age, tumor stage at time of diagnosis, histology, first line therapy and response to first-line therapy are shown in Table I . Additionally, mutation status concerning EGFR and EML4-ALK (if available) is shown. All patients underwent treatment at our Department of Internal Medicine. For blood analyses, an ethics proposal was filed and accepted by the Ethics Committee of the University of Ulm (application no. 09/10).
Pre-treatment peripheral blood [anti-coagulated with ethylenediaminetetraacetic acid (EDTA)] was obtained at date of diagnosis and in the course of following visitations during tumor therapy. For analyses described in these experiments we used blood samples from the date of diagnosis.
Ficoll density gradient centrifugation peripheral blood mononuclear cells (PBMCs) were resuspended in fetal calf serum (FCS; 20%) and 10% DMSO (1x10 7 cells/sample) and cryopreserved as previously described (22) .
HLA-typing by flow cytometry. All peptides used in our experiments were HLA-A * 0201 restricted. To identify HLA-A * 0201 positive cells, flow cytometry was used (Fig. 1 ). Cells were incubated with an FITC labeled monoclonal anti-HLA-A * 0201 antibody (BD, Heidelberg, Germany). As positive and negative control, the T2 and the K562 cell lines were used, respectively. After incubation at 4˚C for 20 min in the dark and after washing twice, stained cells were analyzed by flow cytometry as previously described (23) . From 33 screened patients, 14 were eligible for further experiments.
Peptides used in experiments. The peptides used in our experiments were derived from the well known TAAs RHAMM, PRAME, WT1, from hTERT, survivin, MAGE-A3, G250, HER2, Aurora kinase (Aura) A and B. Except for the peptides derived from Aurora kinases (Aura A1 and Aura B1) all peptides are well known (11, (24) (25) (26) . The entire amino acid sequences of Aura A1 and Aura B1 were screened for HLA-A * 0201 binding T cell epitopes using the algorithms of the SYFPEITHI (www. syfpeithi.de), the Rankpep (http://imed.med.ucm.es/tools) and the HLA-Bind (www-bimas.cit.nih.gov) software programs. For the novel antigens, >10 HLA-A * 0201-binding peptides were predicted and these Aurora kinase-derived peptides were tested in 20 healthy volunteers and 14 lung cancer patients at primary diagnosis. The peptides were purchased from GL Biochem Ltd., Shanghai, China and Thermo Fisher Scientific, Ulm, Germany.
The sequences of the peptides used in our experiments are shown in Table II . Peptides from cytomegalovirus and influenza virus were used as positive controls due to their endemic occurrence (Table II) .
Mixed lymphocyte peptide culture (MLPC).
PBMCs from patients and healthy volunteers were selected by magnetic beads through a magnetic-activated cell-sorting (MACS) column (Miltenyi Biotec, Bergisch Gladbach, Germany). CD8 -antigen presenting cells (APCs) were irradiated with 30 Gy and pulsed for 2 h with either a TAA-derived peptide or a control peptide at a concentration of 20 µg/ml. For all peptides, as well as for the control peptides, the same conditions and reagents were used as previously described (27) .
ELISpot analysis. ELISpots were performed ex vivo on cultured patient cells and the T2 cell line as APCs. Briefly, the irradiated CD8 -fraction of autologous patient PBMCs pulsed with peptide was used as APCs for the CD8 + fraction in MLPC. After 8 days of MLPC culture, the T2-cell line pulsed with peptide was used as APCs in the ELISpot. IFNγ and GrB ELISpot assays were performed as previously described (22, 27) . Fig. 2 shows an exemplary ELISpot detecting specific CTL response of an analyzed lung cancer patient.
Results

Specific T cell response to different TAAs.
Due to the HLA restriction of the peptide used in our analyses, 14 (42%) of 33 screened patients were eligible for further experiments after determining HLA-A * 0201 positivity by FACS analysis (Fig. 1 ). Due to the restriction of patient material, not all peptides could be analyzed for each patient (HER2, n=10; G250, n=12; hTERT; survivin; G250; MAGE-A3 and AURA A1/B1, n=13 each; Table II ). Using interferon γ (IFNγ) and granzyme B (GrB) ELISpot assays, specific cytotoxic T cell responses against at least one of these TAAs could be detected in 13/14 patients (93%). In one patient diagnosed as adenocarcinoma, no specific immune responses against any TAAs could be detected (data not shown). Furthermore, 11/14 (79%) patients exhibited T cell responses against at least 2 TAAs (data not shown). The most frequent specific CTL responses were detected against G250 (IFNγ 58/GrB, 58%) and PRAME (57/43%) followed by hTERT (31/23%) and RHAMM (29/29%). Lower frequency was measured against the 2 MAGE-A3 peptides (23/8% and 31/31%, respectively), survivin (23/23%) and WT1 (15/7%; Table III ). Specific T cell responses were also detected against novel peptides from the Aurora kinases A and B. These peptides, Aura A1 and Aura B1, showed specific T cell responses in 36/29% and 29/43% of patients, respectively. Amino acid sequence and the position in the polypeptide chain. Peptides shown in bold were used as positive controls. TAAs, tumorassociated antigens; PRAME, preferentially expressed antigen in melanoma; RHAMM, receptor for hyaluronic acid-mediated motility. Aura A1, Aurora kinase A; Aura B1, Aurora kinase B; MAGE-A3, melanoma-associated antigen 3.
Regarding identification of simultaneous CTL response, IFNγ ELISpot showed that all patients with specific T cell response for epitopes of RHAMM and hTERT also had a CTL response against PRAME. Second, in all patient samples with CTL response against Aura A1, a reaction against the peptide Aura B1 was also detected (Fig. 3) .
Discussion
In the treatment of lung cancer, significant developments have been made towards new therapeutic strategies. One promising option is the use of tumor vaccination. In our study, we demonstrated that peptides derived from different TAAs induce specific CTLs in a high percentage of patients with advanced lung cancer. It is necessary to identify novel peptides that can be used for targeted immunotherapy.
In most of the patients analyzed, specific CTL responses were detected. The methods that we used and the read out of parameters are well established. For both IFNγ and GrB ELISpot results were mostly similar. Different results were detected only for HER2-2 with a trend to significance (p=0.06). GrB ELISpot directly measures release of a cytolytic protein of these activated specific CTLs, while IFNγ ELISpot detects the key cytokine in the complex process of T cell response. One reason for the different results in both ELISpots regarding the HER2 peptide may be that activation with this peptide does lead to a specific T cell response but not to a lytic activity of CTL.
The most frequent specific CTL response was detected for peptides derived from the known TAAs G250/CAIX and PRAME. The carbonic anhydrase IX, G250/CAIX, is a well known TAA, particularly in solid tumors such as renal cell carcinoma. Specific T cell response of CD8 + T cells after activating PBMCs with the G250/CAIX derived peptide could be seen in patients with squamous cell cancer of head and neck. In 3/4 patients, specific CTL response was detected by GrB ELISpot, 1/7 by IFNγ ELISpot respectively, (23) . In lung cancer, there are different expression rates ranging from 75 to 95% (28, 29) . For renal cancer, clinical trials have been carried out using a monoclonal antibody against G250 (30,31) ; however, peptide vaccinations are not yet in clinical testing. Our data indicate that this peptide derived from G250/CAIX could be a useful target for tumor vaccination in lung cancer. T cells in a patient with metastatic lung cancer. Positive T cell responses were detected against the tumor-associated antigens PRAME, WT1, hTERT and G250 with a strong intensity. IMP and CMV were used as positive controls. ELISpot, enzyme-linked immunospot; PRAME, preferentially expressed antigen in melanoma. Frequency of T cell responses calculated for each peptide. The most frequent specific CTL responses were detected against G250 and PRAME, followed by hTERT and RHAMM. Lower frequency was measured against the two MAGE-A3 peptides, survivin, and WT1. Specific T cell responses were also detected against novel peptides from the Aurora kinases A and B. IFNγ, interferon γ; ELISpot, enzyme-linked immunospot; PRAME, preferentially expressed antigen in melanoma; RHAMM, receptor for hyaluronic acid-mediated motility. Aura A1, Aurora kinase A; Aura B1, Aurora kinase B. MAGE-A3, melanoma-associated antigen 3.
Second, the preferentially expressed antigen in melanoma (PRAME) derived peptide P3 induced a high CTL activity in the examined lung cancer patients which was confirmed in ELISpot assays. PRAME plays a crucial role in the inhibition of cell differentiation and apoptosis by repressing retinoic receptor signaling and showed a correlation with poor prognosis in high stage neuroblastomas (32, 33) . In previous experiments by our group, the peptide PRAME-P3 induced a specific CTL response in 60% of AML patients (n=10) (11) . PRAME is expressed in several tumor entities, including lung cancer in up to 50% (34) , making it a notable target for immunotherapeutic therapies. There is an ongoing phase I trial testing a new anticancer vaccine for patients with PRAME-positive NSCLC after tumor surgery (30) .
Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) has been defined as a leukemia-associated antigen and various RHAMM-derived HLA-A2-restricted peptides were tested for their immunogenicity by our group. In previous experiments, we generated RHAMM-R3-specific cytotoxic T cells of the peripheral blood from 7 of 13 AML patients. These cells were able to lyse RHAMM-R3 pulsed T2 cells and patient dendritic cells and were even able to lyse untreated AML blasts. It was also shown that RHAMM-R3 is a naturally processed epitope presented on HLA A2. Therefore, a phase I vaccination trial was initiated in which patients developed specific CTL response after 4 vaccinations (22) . Similar results were obtained in patients with chronic lymphocytic leukemia and tumors of the head/neck region (35) .
Since there are no clear data regarding overexpression of RHAMM in lung cancer, further analyses must be conducted.
Aside from these frequent responses against generally well known TAAs, we also analyzed specific T cell response against TAAs that are well known especially in lung cancer, such as hTERT and MAGE-A3. Human telomerase reverse transcriptase (hTERT) is the catalytic subunit of the human telomerase. Data have shown that it is overexpressed in lung cancer in up to 85% of lung cancer patients (36) . Studies have also demonstrated that hTERT overexpression in lung cancer correlates with poor prognosis (37, 38) . Trials evaluating the immunological and clinical response of a peptide vaccination with the optimized peptide telomerase reverse transcriptase p572Y (TERT572Y) showed that CTL response was detected in 76.2% of 21 patients after first vaccination and in 90.9% of 11 patients after the sixth vaccination. An early immunological response correlated with prolonged time to progression and overall survival (17) . In our in vitro experiments, a specific CTL response was detected in 31/23%. In contrast to our results, Bolonaki et al (17) could not measure any specific T cell response by IFNγ ELISpot or pentamer staining before the first vaccination of lung cancer patients. Analysis of more patients will provide further information on the immunogenicity of hTERT peptides. Furthermore, a comparison between CTL response and hTERT expression in tumor tissue is warranted.
Melanoma-associated antigen 3 (MAGE-A3) is expressed in up to 55% of the NSCLC. The rate of expression is correlated with the stage of the disease and a poor prognosis (39) . We examined specific T cell response for the peptides MAGE-A3_01 and MAGE-A3_02 and detected IFNγ production against MAGE-A3_01 in 23% and against MAGE-A3_02 in 31% of the analyzed patients. It could be demonstrated that specific T cells against MAGE-A3_01 generated from healthy volunteers recognize lung carcinoma cells (40) . In previous investigations, 182 NSCLC patients with MAGE-A3 positive tumors demonstrated a positive trend for activity of MAGE-A3 protein vaccine with a relative improvement of DFI and DFS (41) . Based on these data, an ongoing randomized phase III trial, MAGRIT, investigates the efficacy of MAGE-A3 tumor vaccination agents in preventing cancer relapse, when administered after tumor resection in patients with MAGE-A3-positive stages IB, II, and IIIA NSCLC (19) .
Additionally, we analyzed T cell responses against novel peptides. In our experiments, we used the Aurora kinase derived peptides Aura A1 and B1 which also induced specific CTL response at a lower level (30%).
To date, 3 Aurora kinases are identified in mammals. Aurora kinases are serine/threonine kinases which play an essential role in cell mitosis and cell division. Aurora kinase A (Aura A) is localized in the centromers of interphase cells and is essential for formation of mitotic spindle. An ectopic expression may lead to malignant transformation of tissue. Its overexpression has been detected in several tumor tissues, including lung cancer. It could be demonstrated that its overexpression correlates with different histological subtypes of lung cancer, but does not indicate poorer prognosis (42) . Furthermore, there are hints that an overexpression of Aura A is associated with drug resistance of tumor cells (43) . Aurora kinase B (Aura B) is known as the chromosomal passenger protein and is localized in centromers of the prophase to the metaphase-anaphase transition. It is then localized to the midzone spindle during telophase and thereafter to midbody during cytokinesis. Aura B is overexpressed in lung cancer and an excessive overexpression correlates with poorer prognosis (44) . Their frequent expression in lung cancer but also their ability to induce a specific immune response indicates that Aurora kinases could be novel targets in vaccination strategies.
Comparing immune responses against the different peptides could show a simultaneous CTL response in several cases. Regarding IFNγ production, in all patient samples which showed an IFNγ production against RHAMM and hTERT, response against PRAME could also be measured. One explanation for this could be a frequently occurring co-expression of different antigens in lung cancer, which has not yet been described. Recent published data verified a common co-expression of PRAME and MAGE-A3 in tumor tissue of lung cancer patients, which may have a poor prognostic value in some tumor stages (45) . Further analysis of more lung cancer patient samples will provide insight into further epitopes leading to the discovery of usable peptides for polyvalent immunization with stronger efficacy comparing single peptide vaccinations.
Additionally, we observed a simultaneous occurrence of CTL response for the two Aurora kinase peptides, Aura A1 and Aura B1. Immunohistochemical analyses of a working group displayed a co-expression of both Aurora kinases in 33 patients with advanced lung cancer (46) . A frequent co-expression in lung cancer could make them feasible targets for multipeptide vaccination as well. Furthermore, both Aurora kinases share a significant homology in their catalytic domain (47) . An immunogenic peptide, which is found in both kinases, could enlarge the attack surface of a vaccination strategy.
In conclusion, specific T cell responses against several TAAs could be detected for the antigens hTERT, PRAME, G250 and RHAMM in high frequency in patients with lung cancer as well as in lower frequency against epitopes from other antigens. Moreover, novel immunogenic targets such as Aurora kinases A and B have been identified as immunogenic targets in lung cancer. Therefore, several antigen structures are appropriate candidates for immunotargeted approaches in lung cancer patients. Further analysis concerning the relationship between specific CTL response against different tumor antigen peptides and histology, clinical status of the patients and response to therapy, is mandatory. Furthermore, comparison of TAA expression in tumor tissue and specific cytotoxic T cell response will lead to a better understanding of the disease in an immunological manner and may extract patients that are appropriate candidates for tumor vaccination.
